Total Payments
$934.81
2024 Payments
$685.01
Companies
4
Transactions
7
Medicare Patients
826
Medicare Billing
$132,931
Payment Breakdown by Category
Research$439.48 (47.0%)
Other$325.00 (34.8%)
Food & Beverage$170.33 (18.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $439.48 | 2 | 47.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $325.00 | 2 | 34.8% |
| Food and Beverage | $170.33 | 3 | 18.2% |
Payments by Type
General
$495.33
5 transactions
Research
$439.48
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $439.48 | 2 | $0 (2024) |
| GENZYME CORPORATION | $325.00 | 2 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $124.80 | 1 | $0 (2022) |
| Bausch & Lomb Americas Inc. | $45.53 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $685.01 | 5 | Regeneron Pharmaceuticals, Inc. ($439.48) |
| 2022 | $249.80 | 2 | GENZYME CORPORATION ($125.00) |
All Payment Transactions
7 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/25/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $302.23 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% • Category: ONCOLOGY | ||||||
| 09/19/2024 | Bausch & Lomb Americas Inc. | XIIDRA (Drug) | Food and Beverage | In-kind items and services | $23.94 | General |
| Category: Ophthalmology | ||||||
| 09/19/2024 | Bausch & Lomb Americas Inc. | XIIDRA (Drug), XIIDRA | Food and Beverage | In-kind items and services | $21.59 | General |
| Category: Ophthalmology | ||||||
| 06/18/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $137.25 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% • Category: ONCOLOGY | ||||||
| 03/12/2024 | GENZYME CORPORATION | CAPRELSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $200.00 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 05/12/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $124.80 | General |
| 03/15/2022 | GENZYME CORPORATION | CAPRELSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $125.00 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% | Regeneron Pharmaceuticals, Inc. | $439.48 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 198 | 428 | $144,725 | $38,437 |
| 2022 | 3 | 128 | 280 | $91,153 | $25,549 |
| 2021 | 5 | 200 | 384 | $109,896 | $31,321 |
| 2020 | 8 | 300 | 618 | $146,873 | $37,625 |
Total Patients
826
Total Services
1,710
Medicare Billing
$132,931
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 75 | 165 | $51,606 | $12,618 | 24.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 38 | 89 | $33,785 | $9,978 | 29.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 20 | 70 | $26,530 | $7,942 | 29.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 26 | 59 | $18,452 | $4,621 | 25.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 13 | 13 | $5,832 | $1,816 | 31.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 26 | 32 | $8,520 | $1,461 | 17.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 29 | 82 | $30,586 | $9,792 | 32.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 51 | 113 | $34,239 | $8,652 | 25.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 14 | 26 | $9,698 | $3,147 | 32.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 13 | 30 | $9,090 | $2,405 | 26.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 21 | 29 | $7,540 | $1,552 | 20.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 69 | 163 | $49,389 | $13,231 | 26.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 36 | 68 | $25,364 | $8,325 | 32.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 17 | 36 | $10,908 | $2,971 | 27.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 43 | 54 | $14,040 | $2,903 | 20.7% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 22 | 41 | $5,043 | $2,024 | 40.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 13 | 22 | $5,152 | $1,866 | 36.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 83 | 278 | $73,392 | $17,566 | 23.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 34 | 55 | $18,083 | $5,074 | 28.1% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 59 | 107 | $13,161 | $4,392 | 33.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 62 | 86 | $19,440 | $3,589 | 18.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 15 | 15 | $5,643 | $2,119 | 37.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 11 | 34 | $8,754 | $2,083 | 23.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 14 | 16 | $2,448 | $1,054 | 43.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 11 | 16 | $2,608 | $882.26 | 33.8% |
About Dr. Ariel Birnbaum, M.D
Dr. Ariel Birnbaum, M.D is a Hematology & Oncology healthcare provider based in Providence, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1942212790.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ariel Birnbaum, M.D has received a total of $934.81 in payments from pharmaceutical and medical device companies, with $685.01 received in 2024. These payments were reported across 7 transactions from 4 companies. The most common payment nature is "" ($439.48).
As a Medicare-enrolled provider, Birnbaum has provided services to 826 Medicare beneficiaries, totaling 1,710 services with total Medicare billing of $132,931. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Providence, RI
- Active Since 08/12/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1942212790
Products in Payments
- LIBTAYO (Biological) $439.48
- CAPRELSA (Drug) $325.00
- XIIDRA (Drug) $45.53
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Providence
Ritesh Rathore, Md, MD
Hematology & Oncology — Payments: $324,296
Hematology & Oncology $324,296
Anthony Mega, Md, MD
Hematology & Oncology — Payments: $193,307
Hematology & Oncology $193,307
Dr. Adam Olszewski, M.d, M.D
Hematology & Oncology — Payments: $47,507
Hematology & Oncology $47,507
John Reagan, Md, MD
Hematology & Oncology — Payments: $35,520
Hematology & Oncology $35,520
Hina Khan, M.d, M.D
Hematology & Oncology — Payments: $19,225
Hematology & Oncology $19,225
Dr. Joseph Dibenedetto, Md, MD
Hematology & Oncology — Payments: $6,205
Hematology & Oncology $6,205